501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo

剂量范围研究 白癜风 医学 双盲 测距 随机对照试验 外科 皮肤病科 病理 地理 大地测量学 替代医学 安慰剂
作者
Thierry Passeron,Khaled Ezzedine,Iltefat Hamzavi,Nanja van Geel,Bethanee J. Schlosser,Xiaofei Hu,Xiaohong Huang,David Rosmarin,John E. Harris,Heidi S. Camp,Amit G. Pandya
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:190 (Supplement_2): ii65-ii66 被引量:2
标识
DOI:10.1093/bjd/ljad498.066
摘要

Abstract Introduction & Objectives Janus kinase (JAK) inhibition is a promising approach for the treatment of vitiligo. Here, we report the clinical efficacy and safety of upadacitinib (UPA), an oral JAK inhibitor, in a phase 2b multicenter, randomized, double-blind, placebo-controlled study of adults with extensive non-segmental vitiligo (NSV). Materials & Methods Eligible patients were aged 18–65 years with NSV, a Facial Vitiligo Area Scoring Index (F-VASI) of ≥0.5, and a Total Vitiligo Area Scoring Index (T-VASI) of ≥5 at baseline. This 52-week study (NCT04927975) comprised 2 periods. In period 1, patients were randomly assigned to once daily UPA 22 mg (UPA22), UPA 11 mg (UPA11), UPA 6 mg (UPA6), or placebo (PBO) for 24 weeks of treatment. In a 28-week blinded extension (period 2), patients receiving UPA during period 1 continued their respective regimens; patients who received PBO in period 1 were pre-assigned to either UPA11 or UPA22. Clinical efficacy endpoints evaluated through week 36 included percent change from baseline (%CFB) in F-VASI (week 24, primary endpoint), reductions from baseline in F-VASI of ≥50% (F-VASI 50) and ≥75% (F-VASI 75), %CFB in T-VASI, and reduction from baseline in T-VASI of ≥50% (T-VASI 50). Safety data as of January 13, 2023 (data cutoff date) are presented. Results Of the 185 patients enrolled in period 1, 165 (89.2%) continued to period 2. At baseline, 68% of patients had extensive vitiligo (T-VASI > 10), and 71% had active vitiligo. At week 24, the %CFB in F-VASI was greater with UPA11 (−35.6%) and UPA22 (−34.0%) vs PBO (−14.4%; nominal P = .005 and P = .013, respectively). A greater proportion of patients achieved F-VASI 50 and F-VASI 75 with UPA11 (38.3%, 19.1%) and UPA22 (39.5%, 14.0%) vs PBO (10.9%, 2.2%; nominal P < .05 for both doses and for both endpoints). Likewise, the %CFB in T-VASI was greater with UPA11 (−17.3%) and UPA22 (−20.7%) vs PBO (−6.4%; nominal P = .026 and P = .005, respectively). A higher percentage of patients achieved T-VASI 50 with UPA22 (11.6%) than with PBO (2.2%; nominal P = .027). UPA efficacy continued to improve through week 36, with %CFB in F-VASI for UPA6, UPA11, and UPA22 of −20.8%, −44.9% and −47.7%, respectively. At week 36, F-VASI 50 was achieved with UPA6, UPA11, and UPA22 by 34.2%, 54.3% and 61.5% of patients and F-VASI 75 by 15.8%, 40.0%, and 30.8%, respectively. At week 36, %CFB in T-VASI for UPA6, UPA11 and UPA22 were −24.3%, −32.0% and −37.6%, with 10.5%, 20.0% and 19.2% of patients, respectively, achieving T-VASI 50. Treatment-emergent adverse event (TEAE) rates were generally similar with UPA and PBO in period 1 (most common TEAEs: COVID-19, acne, fatigue, and headache) and were similar across treatment arms in period 2. One death adjudicated as undetermined/unknown cause and deemed by the investigator to have no reasonable possibility of being related to study drug occurred in the UPA22 group (period 1). One adjudicated event of nonfatal ischemic stroke occurred with UPA11 (period 2). There were no adjudicated events of venous thromboembolism, gastrointestinal perforation, or events of opportunistic infection, active tuberculosis, or malignancy. Conclusion Treatment with UPA for 24 weeks resulted in greater improvements vs PBO in the clinical outcomes of adults with extensive NSV. Observed clinical efficacy continued to improve through week 36 with UPA treatment. UPA was generally well tolerated, with no new safety signals ­identified.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
twinkle发布了新的文献求助10
1秒前
saisyo发布了新的文献求助10
1秒前
九卫完成签到,获得积分10
2秒前
2秒前
2秒前
2秒前
catalyst发布了新的文献求助10
3秒前
4秒前
suki完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
6秒前
renheit发布了新的社区帖子
7秒前
7秒前
8秒前
梁三柏应助byyyy采纳,获得20
8秒前
Om发布了新的文献求助10
10秒前
Lucas应助,,,采纳,获得10
11秒前
11秒前
陈瑶发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
12秒前
yydragen应助wjx采纳,获得30
12秒前
12秒前
13秒前
ziyue发布了新的文献求助10
16秒前
童白翠发布了新的文献求助10
17秒前
一方通行发布了新的文献求助10
18秒前
华仔应助老迟到的沛萍采纳,获得10
18秒前
18秒前
18秒前
Sunrise发布了新的文献求助10
18秒前
九思完成签到,获得积分10
19秒前
九柒完成签到,获得积分10
19秒前
英俊的铭应助沉静丹寒采纳,获得30
20秒前
20秒前
三里墩头应助过时的又槐采纳,获得10
22秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975250
求助须知:如何正确求助?哪些是违规求助? 3519625
关于积分的说明 11199055
捐赠科研通 3255962
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877358
科研通“疑难数据库(出版商)”最低求助积分说明 806298